SELENOP and metabolic dysfunction-associated steatotic liver disease: In patients with T2DM and with NAFLD alike, SEPP1, a selenium-carrier protein, correlated with cardiovascular risk factors (eg, subclinical parameters of inflammation and arterial stiffness).89 More recently, angiopoietin-like protein 8 (ANGPTL-8) was pointed as a predictor of significant NAFLD, independent of obesity and insulin resistance, and could also be a potential therapy target of NAFLD.90